299538
Mapping disease in urban informal settlements: A priority for slum health
Methods: Residential addresses of cases from two previous studies conducted in Rio de Janeiro were used to demonstrate feasibility of mapping cases within slums. The first dataset consisted of 500 children attending day care centers with addresses verbally reported and individually geocoded. The second dataset included all TB cases reported (n=13,915) to the Brazilian National Reportable Disease Surveillance System in 2010 with addresses batch geocoded.
Results: For children addresses, 71.6% were georeferenced to at least the street or address level. National reportable disease data was found to have a higher geocoding success rate (99.1%) given neighborhood was designated. Cases clustered along the borders of slum boundaries. Many slum dwellers used a collective address located just outside the slum; street numbers are only available until the slum limits.
Conclusions: Currently, retrospective mapping of slum communities by address is mainly useful at the aggregate level of slum versus non-slum classification. This designation allows public health officials to better quantify health disparities, particularly in the case of middle-income countries with extreme contrasts between rich and poor populations.
Learning Areas:
Protection of the public in relation to communicable diseases including prevention or controlPublic health or related research
Learning Objectives:
Identify inherent difficulties in mapping cases in slum communities
Discuss in-context approaches difficulties in mapping cases in Brazilian slums
Keyword(s): Geographic Information Systems (GIS), Underserved Populations
Qualified on the content I am responsible for because: I am currently a NIH/FIC Global Health Equity Scholar working in Rio de Janeiro, Brazil. My work focuses on creating community health indicators for slums, known as "favelas", in Rio. Mapping these communities has been an outstanding obstacle in developing new methodologies and has required extensive discussion among our research group and collaborators.
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.